Answers are grounded in this paper and cite their sources.
Background Second-generation antipsychotics (SGAs) are commonly prescribed to children and adolescents but are associated with substantial weight gain and cardiometabolic dysfunction. Youth may be particularly vulnerable to these adverse effects, while available pharmacologic interventions remain limited. Metformin, the most studied treatment for antipsychotic-associated weight gain in pediatric populations, generally produces modest benefits. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated substantial efficacy for weight loss and metabolic improvement in adults receiving antipsychotics and are increasingly used to treat obesity in adolescents; however, their use for antipsychotic-associated weight gain in children and adolescents has not been studied. Objective To review the existing evidence supporting the potential use of GLP-1 RAs for antipsychotic-associated weight gain in children and adolescents and to identify gaps in the current literature. Methods A narrative review was conducted examining clinical trials, meta-analyses, systematic reviews, and relevant regulatory and safety data regarding GLP-1 RA use in adults receiving antipsychotics, pediatric populations with obesity or type 2 diabetes, and children and adolescents receiving SGAs. Results Multiple randomized controlled trials and meta-analyses demonstrate that GLP-1 RAs, particularly liraglutide and semaglutide, significantly reduce body weight and improve glycemic and cardiometabolic parameters in adults receiving antipsychotics, including those treated with clozapine and olanzapine. Recent trials of semaglutide have demonstrated clinically meaningful weight loss without worsening psychotic symptoms or clozapine concentrations. In pediatric populations without antipsychotic exposure, GLP-1 RAs are effective for obesity and metabolic disease, with semaglutide demonstrating substantial reductions in BMI and improvements in several cardiometabolic measures. Gastrointestinal adverse effects are the most consistently reported adverse events. Current evidence from randomized trials, meta-analyses, and observational studies does not demonstrate an increased risk of adverse psychiatric outcomes associated with GLP-1 RA treatment. Despite this evidence base, no identified studies have evaluated GLP-1 RAs specifically for antipsychotic-associated weight gain in children or adolescents. Conclusions GLP-1 RAs represent a promising potential treatment for antipsychotic-associated weight gain in pediatric populations, given the convergence of robust adult efficacy data, evidence supporting their use in adolescent obesity, and limited efficacy of currently available pharmacologic interventions. However, the absence of pediatric studies specifically examining antipsychotic-associated weight gain represents a significant evidence gap. Prospective, pediatric-specific trials are needed to establish the efficacy, safety, optimal 2 timing, and long-term metabolic and psychiatric outcomes of GLP-1 RA treatment in youth receiving SGAs.
No takes yet. Share an insight, caveat, or question.
Mindlin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: